Miguel Angel Moreno-Pelayo

Qualified in Biology in the Complutense University, Madrid, Spain and did his fellowship and doctoral work in immunogenetics. Later on he moved to the human genetic field where he has held postdoctoral positions at the Genetics Department of the Hospital Ramón y Cajal in Madrid and in the University of Sussex, UK. He is now the head of Genetics at the Hospital Ramón y Cajal and group leader of the U728 in the CIBER of rare diseases (CIBERER). He is also assistant professor in the Bioengineering Department at the UC3M in Madrid.

During the last fifteen years he has focuses his activity on deciphering the molecular and genetics bases of progressive hearing loss along with the mechanisms of pathogenesis that underlie these group of disorders. His group has mapped and identified several genes involved in autosomal dominant hearing loss. To highlight is the identification of the first microRNA, miR96, responsible for a monogenic disease, the DFNA50 hearing loss. He has also explored the pathogenic mechanism of different mutations as in KCNQ4, ACTG1, EYA4, miR96 or TECTA genes by means of functional studies and the generation of mouse models. As part of the innovative actions his group has developed and commercialized novel tools based on NGS and aCGH for the integral genetic diagnostic of hereditary hearing impairment. His program of research has been supported by the ISCIII, Fundación Ramón Areces, FAPESP and industrial collaborations.